JP-2266 [1] is a small-molecule SGLT1/ 2 dual inhibitor that is designed to help patients with diabetes. It was tested as an adjunct to insulin in type 1 diabetes [2] and also in patients with type 2 diabetes. [3] It is reported to be a better drug candidate than sotagliflozin. [4]
References
- ^ "JP 2266 - AdisInsight". adisinsight.springer.com. Retrieved 23 November 2023.
- ^ Park, Youngjun (1 July 2018). "Antidiabetic Effect of JP-2266, a Novel SGLT1/2 Dual Inhibitor, for the Treatment of Type 1 Diabetes". Diabetes. 67 (Supplement_1). doi: 10.2337/db18-2303-PUB. ISSN 0012-1797.
- ^ "Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients". clinicaltrials.gov. Retrieved 23 November 2023.
- ^ "Jeil's development of diabetes treatment goes as planned". KBR. 25 June 2018. Retrieved 23 November 2023.
JP-2266 [1] is a small-molecule SGLT1/ 2 dual inhibitor that is designed to help patients with diabetes. It was tested as an adjunct to insulin in type 1 diabetes [2] and also in patients with type 2 diabetes. [3] It is reported to be a better drug candidate than sotagliflozin. [4]
References
- ^ "JP 2266 - AdisInsight". adisinsight.springer.com. Retrieved 23 November 2023.
- ^ Park, Youngjun (1 July 2018). "Antidiabetic Effect of JP-2266, a Novel SGLT1/2 Dual Inhibitor, for the Treatment of Type 1 Diabetes". Diabetes. 67 (Supplement_1). doi: 10.2337/db18-2303-PUB. ISSN 0012-1797.
- ^ "Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients". clinicaltrials.gov. Retrieved 23 November 2023.
- ^ "Jeil's development of diabetes treatment goes as planned". KBR. 25 June 2018. Retrieved 23 November 2023.